Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Jan 10, 2019 2:31pm

95 Views

Post# 29214019

RE:RE:Traders ordered the Mackie takedown

I'm not sure what your point is?

Do you not agree that the report is poor and suspicious in its timing?

Do you think it is normal to slash your target price 90% and discuss lower Egrifta sales (this has never been guided)?

bfw

PoorOpinion wrote: A few days ago you were cooing about the rising SP.

One thing more volatile than this stock is SOME of the people on this board. Somebody mentioned it a while back, red days bring out the more emotional, irrational comments on this board.

bfw wrote: The timing of it is very suspicious.

The share price was turning a corner and had rallied up to and just over the 50 DMA on a weekly chart.

The 50 DMA was some natural resistance. Perfect time to short and distort.

I can understand reservations about Trogarzo script numbers but there was zero reason to take down Egrifta estimates. Egrifta has been growing reliably. Finally, the target could have been dropped to $14 rather than $10.20. The traders ordered a shock value drop.

bfw